Blood type does not modify prognosis in patients with COVID-19: Experience in a COVID-19 hospital in Mexico

Introduction: According to reports from China and Europe, there are various clinical and laboratory risk factors that associate with both death and the use of a ventilator in coronavirus disease 2019 (COVID-19). In Wuhan, blood type A was related to these complications, but this factor is unknown for Latin America. Objective was to describe the association of blood type with complications related to COVID-19 infection. Material and methods: A retrospective comparative study from the clinical files of patients cared for in the emergency department between April and May 2020. Results: Data was analyzed from 120 patients hospitalized with COVID-19 infection. There were no differences in age and gender by blood type. Type O was the most frequent (80.8%) followed by type A (11.7%) and type B (7.5%). In univariate analysis, there was no impact of blood type on survival, individually (groups A, B, O) (log rank 0.154). In multivariate analysis, only age influenced prognosis (p =0.004). Above the risk, type O showed no impact on mortality [odds ratio (OR) 1.0119, 95% confidence interval (CI): 0.3898-2.6272, p =0.980] or ventilator use (OR 1.5616, 95% CI: 0.4834-5.0453, p =0.456), likewise for types A and B (OR 0.9882, 95% CI, 0.3806-2.5657). Conclusion: Blood type does not impact prognosis in Mexican patients with COVID-19.

Pregnancy and COVID-19. Considerations in the practice of Hematology

Coronavirus disease 2019 (COVID-19) in a vulnerable population, such as the pregnant woman, fetus, and newborn, requires an establishment of effective and safe strategies focused on the safety of the mother-child binomial. The objective of this report is to present the results of the review of secondary information sources (meta-analysis and systematic review), of the state of the art in the advancement of knowledge of the disease due to COVID-19 during pregnancy. Different reports have insisted that maternal mortality from COVID-19 is low. However, the maternal mortality ratio (MMR) increased from 30.9 to 45.5 deaths per 100,000 births, that is, it showed an increase of 36.32% compared to the same week of 2019. Due to its unprecedented condition and the particular behavior of the COVID-19 disease during the perinatal period, the generation of new data, its integration into accessible information and its epidemiological clinical analysis will inevitably provide new evidence that must be integrated into clinical management and practice. But the issue is not limited to COVID-19, the increase in MMR is 24% for maternal obstetric hemorrhage, 20% for hypertensive disease, and 28.5% for puerperal sepsis. There is no characteristic hematological behavior and the appearance of thrombotic or hemorrhagic complications in the patient with COVID-19, without clinical characteristics similar to those seen in her non-pregnant peers. The global increase in all causes of maternal mortality are not exclusive to COVID-19, which exposes the deficiencies of the health system in terms of primary health care, prenatal surveillance, family planning, among other programs;additional to the impact of COVID-19. The redesign of public policies in terms of primary health care for the entire population is an urgent need, particularly for pregnant women.